The FDA is none too pleased with Human Genome Sciences' (HGSI) new hepatitis C drug Zalbin (albinterferon alfa-2b), but that may be a blessing in disguise given entrenched competition and changing ...
MALVERN, Pa.--(BUSINESS WIRE)--Human Genome Sciences (HGS: NASDAQ: HGSI) announced that BENLYSTA TM met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with ...
Human Genome (HGSI-1.2%) shares are downgraded to Neutral from Buy at Collins Stewart, which lowers its price target to $10 from $17 after results of its Q4 tracking survey for its Benlysta lupus drug ...
ROCKVILLE, Md.--(BUSINESS WIRE)-- Human Genome Sciences, Inc. (NASDAQ:HGSI) announced today that its presentation at the Goldman Sachs 31st Annual Global Healthcare Conference will be webcast and may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback